newswire, breaking biotechnology and pharma news

Tuesday, June 28, 2011

Q&A with Aethlon Medical (OTCBB: AEMD) CEO, Jim Joyce; The Potential for the Hemopurifier® Medical Device in Cancer Immunotherapy

Point Roberts, WA. June 28, 2011 –, a leader in sector stock research presents a new interview in its series of biotech Q&A’s, featuring Jim Joyce, CEO of Aethlon Medical (OTCBB: AEMD), discussing how the Hemopurifier® medical device can be used in Cancer Immunotherapy treatment.

Q&A Interview

Jim, can you begin by explaining to investors the theory behind Cancer Immunotherapy and the various approaches and methods within it?

A: Jim Joyce, CEO of Aethlon Medical (OTCBB: AEMD)

The basis of cancer immunotherapy is the reality that patient survival is primarily determined by the immune system’s ability to recognize and respond to cancer.   So instead of attacking cancer directly with traditional drugs, immunotherapeutic strategies aim to increase immune cell activation or improve the capability of immune cells to identify and attack cancer.

Can you explain to investors how the Hemopurifier® medical device approach differentiates from using drugs as a treatment and how it could potentially impact results? And potentially would there be less side effects to deal with?

A: Jim Joyce, CEO of Aethlon Medical (OTCBB: AEMD)

In cancer care, the purpose of our Hemopurifier® is to shield immune cells from particles released by tumors to accelerate cancer proliferation.  These particles, known as exosomes, trigger the death of immune cells that are needed to combat cancer.  In later-stage cancers, exosomes can snowball to massive levels in the circulatory system.  By selectively removing these exosomes from circulation, we envision our Hemopurifier® will preserve immune function and unlock the capabilities of both traditional and evolving immunotherapeutic drug strategies.  And, as a medical device, oncologists should appreciate a technology that can be combined with other treatments without adding additional drug toxicity or interaction risks.  We believe our Hemopurifier® represents the sole therapeutic strategy to address cancer-enhancing exosomes.

Can you give investors some examples of publicly traded stocks in the Cancer Immunotherapy treatment market?  

A: Jim Joyce, CEO of Aethlon Medical (OTCBB: AEMD)

I would start by looking at organizations that have already advanced cancer immunotherapy drugs into the marketplace.  This would include Dendreon (NASDAQ:DNDN) and Bristol-Meyers Squibb (NYSE:BMY).  Companies with candidate drugs in the clinical pipeline include Roche (OTCPK:RHHBY) and GlaxoSmithKline (NYSE:GSK).

Can you also give us an overview of other key markets and applications for the Hemopurifier® and where do you see your biggest markets down the road?   

A: Jim Joyce, CEO of Aethlon Medical (OTCBB: AEMD)

In addition to capturing exosomes, our Hemopurifier® has demonstrated broad-spectrum activity against infectious viral pathogens.  We are currently conducting a clinical program to demonstrate the ability of our Hemopurifier® to improve outcomes of Hepatitis C infected patients who initiate current standard of care drug therapy.  This market opportunity consists of approximately 170 million infected individuals worldwide.  

About Aethlon Medical (OTCBB: AEMD)

Visit the showcase page on

Get added to the company’s news alerts:

From the Company:  

The Aethlon Medical mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions.  The Aethlon ADAPT™ system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to create therapeutic filtration devices that selectively target the removal of harmful particles from the entire circulatory system.  Our lead therapeutic candidate is the Aethlon Hemopurifier®, a device with broad-spectrum capabilities against viral pathogens and immunosuppressive cancer exosomes.  In human studies, Hemopurifier® therapy has provided significant viral load reductions in HIV and hepatitis C virus infected individuals without the administration of antiviral drugs.  We are now focused on advancing our Hemopurifier® as an adjunct strategy to improve the benefit of established infectious disease and cancer treatment regimens.  Based on studies conducted by government and non-government research organizations, the Hemopurifier® is also a leading broad-spectrum treatment candidate to address bioterror and pandemic threats.  For more information, please visit

James A. Joyce
Chairman, CEO
858.459.7800 x301

About is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal
Research more biotech stocks at the Biotech stocks Directory:

Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC (OTC BB: AEMD) Showcase biotech, biodefense and defense stock on ($one thousand five hundred per month, $five thousand per month in 144 stock) Effective March 15, 2011       

800-665-0411 –  
Source -

No comments:

Post a Comment